Metsera (NASDAQ:MTSR) Shares Gap Up Following Analyst Upgrade

Shares of Metsera, Inc. (NASDAQ:MTSR) gapped up before the market opened on Tuesday after Guggenheim raised their price target on the stock from $56.00 to $62.00. The stock had previously closed at $30.39, but opened at $32.35. Guggenheim currently has a buy rating on the stock. Metsera shares last traded at $37.42, with a volume of 959,269 shares changing hands.

A number of other equities research analysts also recently issued reports on the company. Evercore ISI started coverage on Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating for the company. Bank of America initiated coverage on Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $38.00 price objective on the stock. Finally, Cantor Fitzgerald initiated coverage on Metsera in a research note on Tuesday, February 25th. They set an “overweight” rating on the stock.

Institutional Trading of Metsera

Institutional investors and hedge funds have recently bought and sold shares of the company. Deutsche Bank AG bought a new position in shares of Metsera during the first quarter valued at approximately $374,000. Price T Rowe Associates Inc. MD bought a new position in Metsera in the 1st quarter worth approximately $42,395,000. American Century Companies Inc. bought a new position in Metsera in the 1st quarter worth approximately $7,791,000. Vanguard Group Inc. bought a new position in Metsera in the 1st quarter worth approximately $39,932,000. Finally, Alpha Wave Global LP bought a new position in Metsera in the 1st quarter worth approximately $64,894,000.

Metsera Price Performance

The business has a fifty day moving average of $23.40.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.